Earnings Call · Q3 FY2025·2025-11-13

Q3 25EPS -27.27%·Rev n/aQ2 25EPS -25.00%·Rev n/aQ1 25EPS n/a·Rev n/aQ4 24EPS -78.75%·Rev n/a⚠ consensus missing

Starling Oncology, Inc. TOI

Mark Hueppelsheuser — Investor Relations or Communications Officer

Daniel Virnich — Chief Executive Officer

Rob Carter — CFO

−10.2%1d on move date−8.5% vs SPY3d+9.9%5d−4.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TOI calls or request research access.

More TOI calls Browse calls Request research access